A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FAZIRSIRAN IN THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY¿ASSOCIATED LIVER DISEASE WITH METAVIR STAGE F2 TO F4 FIBROSIS

Registry ID

TAK-999-3001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

TAKEDA DEVELOPMENT CENTER AMERICAS INC

Start date

2025-02-09

Last update

2023-01-24

Conditions

• ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

Related clinical trials

• A PHASE 1B/2A OPEN-LABEL SINGLE ASCENDING DOSES (SAD) AND MULTIPLE ASCENDING DOSES (MAD) RESEARCH STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS IN PARTICIPANTS WITH AATD PI*ZZ ON WVE-006 (RESTORAATION-2)
• A PLACEBO-CONTROLLED, MULTI-DOSE, PHASE 2/3 STUDY TO DETERMINE THE SAFETY, TOLERABILITY AND EFFECT ON LIVER HISTOLOGIC PARAMETERS IN RESPONSE TO ARO-AAT IN PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
• AN OPEN-LABEL, MULTI-DOSE, PHASE 2 STUDY TO DETERMINE THE SAFETY, TOLERABILITY AND EFFECT ON CIRCULATING AND INTRAHEPATIC ALPHA-1 ANTITRYPSIN LEVELS OF ARC-AAT AS EVIDENCED BY CHANGES IN LIVER BIOPSY IN PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

View on source registry